Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

It’s hard to feel much worse than when tired and jet-lagged from the 16-hour flight to Thailand. Perhaps only after then ...

Topline data were announced from a phase 3 trial evaluating DTX301 (avalotcagene ontaparvovec) for the treatment of OTC deficiency.

AOM Infusion ("AOM"), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma's limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) ...

A single intravenous ketamine infusion was safe and well-tolerated in older adults with mild cognitive impairment (MCI) and depression (MCI-D), with no serious adverse events (AEs) reported, a small ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia HELSINKI, 12 March 2026 - Aplagon, a ...

The Citizens Life Sciences Conference 2026 March 11, 2026 10:45 AM EDTCompany ParticipantsHelen Torley - President, ...

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...